Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | BLM | P54132 | 3/20 | 0.73 |
| ▸ | HTR2A | P28223 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.73 |
| ▸ | HTR1A | P08908 | 2/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.73 |
| ▸ | HTR2C | P28335 | 2/20 | 0.73 |
| ▸ | HTR2B | P41595 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.73 |
| ▸ | HTR7 | P34969 | 1/20 | 0.73 |
| ▸ | MTOR | P42345 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307776 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL29382361 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL30405928 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL454983 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL19871231 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| Tryptophan SCHEMBL7091652 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| D-Tryptophan SCHEMBL8103547 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| Tryptophan SCHEMBL7091650 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| D-Tryptophan SCHEMBL8103544 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL28473836 | 0.93 | HTR2A (0.64) | KMT2ABLMHTR2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| CN-112041301-A | Compounds having iron death inducing activity and methods of use thereof | 费罗治疗公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20070111930-A1 | PROCESS FOR PREPARING VAPREOTIDE | DR. REDDY'S LABORATORIES, INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2003081199-A2 | ANTIFOULING AGENT | INNOVENTUS PROJECT AB (SE) | 2003-10-02 | — | — | WO | disclosed |
| EP-0203031-B1 | BIOLOGICALLY ACTIVE LYSINE CONTAINING OCTAPEPTIDES | The Administrators of The Tulane University Educational Fund (US) | 1992-07-29 | — | — | EP | disclosed |
| US-4725577-A | Biologically active lysine containing octapeptides | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1988-02-16 | — | — | US | disclosed |
| US-4650787-A | SOMATOSTATIN ANALOG | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND OF NEW ORLEANS, LOUISIANA, THE, | 1987-03-17 | — | — | US | disclosed |
| EP-0203031-A2 | Biologically active lysine containing octapeptides | The Administrators of The Tulane University Educational Fund (US) | 1986-11-26 | — | — | EP | disclosed |
| US-4224199-A | ANTIDIABETIC | MEYERS CHESTER A | 1980-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | KMT2A 2510/4885BLM 2168/4885HTR2A 3134/4885 |
| US-20070111930-A1 | PROCESS FOR PREPARING VAPREOTIDE | VIP, SSTR4, SSTR5 | KMT2A 4158/4885BLM 3365/4885HTR2A 3297/4885 |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | AIFM2, GPX4, GPX1 | KMT2A 2475/4885BLM 2902/4885HTR2A 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.